UnitedHealth (UNH) vs S&P 500

UNH at $276.23 billion market cap represents approximately 0.7 percent of the S&P 500. Within healthcare (approximately 12 percent of S&P), UNH is the second-largest holding after Eli Lilly. The S&P 500 healthcare sector at 12 percent is the third-largest sector after technology (~30 percent) and financials (~13 percent).

The UNH/SPY ratio currently trades at approximately 0.495 (UNH $350.82 / SPY $708). The ratio peaked near 0.85 in October 2023 (UNH approaching $530, SPY at $590) and bottomed near 0.43 in mid-2024 during the Change Healthcare cyber and DOJ investigation announcement period. The current 0.495 reflects partial recovery as Q1 2026 results stabilized and management raised guidance.

UNH lost 30 percent peak-to-trough during 2024-2025 from $530 in October 2023. Three drivers compounded simultaneously, producing one of the largest single-stock drawdowns in S&P 500 history.

First, Change Healthcare cyber attack: February 2024 ransomware attack on UNH-owned Change Healthcare disrupted claims processing across the US healthcare system for weeks. The incident produced approximately $2 billion in remediation costs, Senate hearings, and significant reputation damage. UNH stock declined roughly 20 percent over the subsequent 8 weeks.

Second, Medicare Advantage margin compression: 2024 CMS reimbursement updates were less generous than expected, while medical-cost trends accelerated post-COVID. UnitedHealthcare margins compressed from 6 percent in 2023 to 5 percent in 2024 to approximately 4 percent in 2025. Combined with a 50 percent share-of-MA market position, the margin compression was material.

Third, DOJ investigation: announced 2024 into Medicare Advantage billing practices, focusing on diagnoses that increased federal payments. Senate Permanent Subcommittee on Investigations parallel inquiry accused UNH of "aggressively gaming" MA. The combined regulatory overhang remained throughout 2025.

Healthcare is supposed to be defensive. UNH historically traded as a quality-defensive name with stable cash flows, dividend growth, and lower volatility than SPY. The 2024-2025 episode broke this narrative because UNH faced simultaneous idiosyncratic stress that overwhelmed any defensive macro flow.

The lesson for the UNH-vs-SPY relationship: idiosyncratic stress can dominate defensive characteristics for extended periods. The UNH-vs-SPY pair-trade thesis (long UNH for defense) is conditional on absence of UNH-specific issues. When such issues emerge (cyber attacks, regulatory investigations, margin compression episodes), the defensive characteristic disappears and UNH can underperform SPY by 50+ percentage points cumulatively.

The 2026 partial recovery suggests the worst is behind UNH. But the pair-trade thesis remains reduced confidence: how reliably can UNH function as defensive given the demonstrated vulnerability to specific stress?

From 2010 through 2023 (October 2023 peak), UNH outperformed SPY by approximately 350 percentage points cumulatively. UNH gained roughly 1,400 percent over the period versus SPY 360 percent. The structural drivers of this outperformance: Medicare Advantage enrollment expansion (25 percent of Medicare-eligible in 2010 to 53 percent in 2024), Optum services scaling (UnitedHealth's diversification into healthcare services), and consistent margin expansion through pricing discipline.

The 2010-2023 era was the UNH structural compounder narrative: stable double-digit earnings growth with low volatility, consistent dividend increases, and material multiple expansion as the market rewarded the integrated insurance-plus-services model.

The 2024-2025 disruption represents the first major break in this trajectory. The 2026 question is whether UNH returns to its long-run outperformance pattern (now potentially compressed by tighter MA reimbursement and DOJ overhang) or whether the structural growth thesis has been permanently impaired.

Pre-2024, UNH realized volatility was approximately 22 percent annualized versus SPY 15-17 percent. The 1.4x volatility ratio was modest relative to other healthcare stocks. UNH was viewed as among the lowest-vol single names in healthcare, behind staples like JNJ and ABBV.

2024-2025 saw UNH realized volatility spike to approximately 32 percent (annualized) at peak stress periods. The current April 2026 volatility is approximately 25 percent, elevated versus pre-2024 baseline reflecting residual DOJ overhang and event-risk premium.

The correlation between UNH and SPY varied significantly. Pre-2024 60-day correlation averaged 0.55. During the 2024-2025 stress period, correlation dropped to 0.20-0.30 as UNH moved on idiosyncratic factors. The current correlation is approximately 0.45, reflecting partial reintegration but residual idiosyncratic risk.

UNH year-to-date 2026 +5 percent vs SPY +1 percent (4 percentage point outperformance). The recovery reflects three factors. First, management raised 2026 EPS guidance to at least $18.25, indicating margin recovery from 2024-2025 trough. Second, Q1 2026 results showed Medicare Advantage cost trends moderating, suggesting the worst margin compression has passed. Third, the DOJ investigation has moved from initial-reporting phase to lengthy procedural phase without immediate adverse rulings.

Morgan Stanley named UNH a Top Pick at $375 target, implying approximately 7 percent upside. The bull case: 2026 EPS comes in above $18.25, Q3 2026 MA bid season produces rationalized pricing, DOJ investigation produces no material findings, and UNH multiple re-rates from current 19x forward to pre-2024 levels of 22-25x. The bear case: 2026 MA enrollment declines (vs current low-single-digit growth expectation), DOJ investigation produces material findings, and the multiple compression persists.

Healthcare-as-defensive in recessions has historical support but with caveats. The 2008-2009 recession: UNH gained 5 percent peak-to-trough while SPY fell 56 percent (61 percentage point UNH outperformance). The 2020 COVID recession: UNH gained 12 percent while SPY fell 34 percent (46 percentage point UNH outperformance).

Both historical episodes showed UNH defensive characteristics working. The 2024-2025 stress was not a recession (SPY actually gained); it was UNH-specific. The defensive thesis remains untested in a recessionary scenario in the post-Change-cyber, post-DOJ era.

For any 2026 recession scenario (demand-driven from Iran war, tariffs, or other shocks), expectations for UNH defensive behavior should be moderated by the demonstrated 2024-2025 vulnerability. Historical 60-percentage-point recession outperformance vs SPY may compress to 20-30 percentage points if regulatory and reimbursement overhangs persist.

UNH 2026 EPS guidance >=$18.25 implies approximately 30 percent year-over-year growth from 2025 EPS of approximately $14.20 (down from 2023 peak of $25). The substantial decline 2023-to-2025 reflects margin compression and Change cyber costs. The 2026 recovery to $18.25 represents partial restoration but not full recovery to 2023 levels.

SPY 2026 EPS consensus is approximately $268, up 3 percent from 2025 $260. The 30 percent vs 3 percent earnings-growth differential supports continued UNH outperformance through 2026 if achieved. However, the achievement depends on Q2 and Q3 2026 results showing continued MA cost moderation and absence of new DOJ developments.

UNH 2027 consensus EPS is approximately $20.50, up 12 percent from 2026 guidance. SPY 2027 EPS consensus is approximately $290, up 8 percent. The growth differential narrows but UNH retains advantage through 2027 absent further stress.

For pair traders, the UNH/SPY ratio currently trades at 0.495. The 12-month range is 0.43 to 0.55. The 5-year range is 0.43 to 0.85. Above 0.55 indicates UNH extended outperformance; below 0.46 indicates renewed UNH stress.

Long UNH / short SPY captures the UNH-recovery bet: benefits from DOJ resolution, MA margin recovery, and broader earnings-growth differential. Short UNH / long SPY benefits from new UNH-specific stress (DOJ adverse ruling, additional cyber incident, MA margin re-compression) or risk-on rotation favoring tech and growth. Position sizing should account for UNH 25 percent annualized volatility versus SPY 15-17 percent.

The pair has produced significant cumulative returns over the 2023-2026 cycle: long UNH short SPY would have lost approximately 55 percentage points through 2024-2025 then gained approximately 4 percentage points in 2026 partial recovery. The net outcome is highly path-dependent on DOJ investigation resolution and broader risk-on/risk-off rotation.

UNH at $350.82, SPY at $708, ratio at 0.495. UNH 2026 EPS guidance >=$18.25 (up ~30% YoY). Year-to-date UNH +5 percent vs SPY +1 percent. Morgan Stanley Top Pick at $375 target. Q1 2026 results stabilized; DOJ investigation in procedural phase.

Forward-looking: UNH Q2 2026 earnings (mid-July) will provide updated MA cost-trend data. The 2026 MA bid season (Q2-Q3) will determine 2027 enrollment trajectory. The DOJ investigation timeline is uncertain; resolution within 12-18 months is possible. SPY drivers include April 30 Q1 2026 mega-cap tech earnings, Iran war duration, and macro indicators.

Watch the UNH/SPY ratio for any move outside the 0.46-0.55 range. Above 0.58 indicates DOJ overhang clearing (premium-multiple recovery underway); below 0.45 indicates renewed UNH stress (likely DOJ adverse development). The pair offers asymmetric upside if 2026 stabilization continues and asymmetric downside if any of the three idiosyncratic risks (DOJ, cyber, MA margins) reactivate.